Navigation Links
Despite Recessionary Pressures, Patient and Surgeon Demand Will Drive the Joint Arthroplasty and Fixation Bone Cement Market by 7% Annually Through 2013
Date:10/6/2009

WALTHAM, Mass., Oct. 6 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, patients and surgeons are driving demand for elective orthopedic procedures. Recessionary pressures slowed growth in joint arthroplasty procedures between 2008 and 2009; however, novel technology, such as hip resurfacing and joint revision implants, is enabling a wider range of patients to be treated in the US, Europe, and Japan, while the burgeoning middle classes in Brazil, China, and India are opting for elective joint replacement procedures and driving global growth by 7% annually through 2013.

MRG's Global Markets for Bone Cement and Accessories 2009 report finds that as device benefits emerge, their adoption will increase in all countries under study. The resulting procedure volume growth will propel sales of bone cement, cement mixing/delivery systems, and cement spacer molds. The prefabricated cement spacer mold segment will outperform the overall market, with 10% annual growth fueled by the release of positive clinical data for this relatively new technology.

In the US and Europe, a two-stage revision procedure has become the standard of care for treating infected hip and knee arthroplasties. Silicone-based cement spacer molds allow the surgeon to create an antibiotic cement implant in the shape of a prosthetic hip or knee implant. This antibiotic-loaded implant preserves normal leg length, allows for early patient mobilization, and quickly delivers the antibiotics locally to the periprosthetic space, to prevent further infection.

"Although cement spacer molds are gaining surgeon acceptance, the relatively high device price can be prohibitive, particularly in facilities with restricted budgets and in countries where patients pay for the vast majority of medical expenses out-of-pocket," says Melissa Hussey, Analyst at MRG. "As of 2009, China and India had not approved the use of cement spacer molds, and their adoption has been limited in Brazil due to the additional cost they add to the procedure. Globally, however, the market for cement spacer molds will grow considerably over the next five years."

MRG's new report, Global Markets for Bone Cement and Accessories 2009 provides important insight into surgical trends that will fuel device use and market growth through 2013. Additionally, the report provides full breakdowns of cemented hip, knee, and small-joint replacement procedures by type and unit sales for bone cement, cement mixing and delivery systems, and cement spacer molds by subtype, including five-year forecasts, up-to-date country-level market shares, and in-depth qualitative insights.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com

SOURCE Millennium Research Group


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
3. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
4. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
5. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
6. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
7. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
8. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
9. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
10. Study Suggests that NGAL Identifies Acute Kidney Injury Early in ICU Patients
11. Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ALBANY, New York , March 28, 2017 /PRNewswire/ ... features a largely consolidated vendor landscape, with the top ... and Agilent Technologies accounting for a significant 49% of ... in a recent report. The vendor landscape is intensely ... large share in the overall market. These factors have ...
(Date:3/28/2017)... 2017 This morning,s research ... stocks: The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals ... and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN ... space which is governed by the same governing ... the industry are wholesalers, retailers, pharmacies, and benefit ...
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary of ... the company,s board of directors: ... Mr. Gabrieli will serve as chairman of the board of ... chief commercial officer of Forest Laboratories. ... Partners. "We are excited to announce ...
Breaking Medicine Technology:
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of two biometric time and attendance tracking products: the new NCheck Cloud Bio ... Cloud Bio Attendance uses biometric face recognition to enable users to check in ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... direct measurement of corrosive ions found in power plant water and steam. , ... such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is ... dentists should be aware of when utilizing dental laboratories and technicians that create ...
Breaking Medicine News(10 mins):